Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8239294 | 0.87 | IL2 (0.67) | IL2ABL1 | |
| SCHEMBL449982 | 0.86 | IL2 (0.63) | IL2ABL1 | |
| SCHEMBL2817819 | 0.85 | IL2 (0.65) | IL2ABL1 | |
| SCHEMBL2816606 | 0.85 | IL2 (0.61) | IL2ABL1 | |
| SCHEMBL2817751 | 0.84 | IL2 (0.69) | IL2ABL1 | |
| SCHEMBL2817899 | 0.84 | IL2 (0.61) | IL2ABL1 | |
| SCHEMBL15853490 | 0.83 | IL2 (0.62) | IL2ABL1 | |
| SCHEMBL2816403 | 0.83 | IL2 (0.65) | IL2ABL1 | |
| SCHEMBL2819267 | 0.83 | IL2 (0.62) | IL2ABL1 | |
| SCHEMBL2812251 | 0.83 | IL2 (0.62) | IL2ABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120064121-A1 | PYRIDINE COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (MA) | 2012-03-15 | — | — | US | claimed |
| US-20120065239-A1 | PROCESS FOR THE PRODUCTION OF AMIDES | SYNGENTA LIMITED (GB) | 2012-03-15 | — | — | US | claimed |
| EP-2182808-A1 | PYRIDINE COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | Synta Pharmaceuticals Corporation (US) | 2010-05-12 | — | — | EP | claimed |
| WO-2009017819-A1 | PYRIDINE COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2009-02-05 | — | — | WO | claimed |
| US-20120065239-A1 | PROCESS FOR THE PRODUCTION OF AMIDES | SYNGENTA LIMITED (GB) | 2012-03-15 | — | — | US | disclosed |
| US-20120064121-A1 | PYRIDINE COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (MA) | 2012-03-15 | — | — | US | disclosed |
| US-20120064121-A1 | PYRIDINE COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (MA) | 2012-03-15 | — | — | US | disclosed |
| US-7994341-B2 | Process for the production of amides | SYNGENTA LIMITED (GB) | 2011-08-09 | — | — | US | disclosed |
| EP-2182808-A1 | PYRIDINE COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | Synta Pharmaceuticals Corporation (US) | 2010-05-12 | — | — | EP | disclosed |
| WO-2009017819-A1 | PYRIDINE COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2009-02-05 | — | — | WO | disclosed |
| WO-2009017819-A1 | PYRIDINE COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2009-02-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120064121-A1 | PYRIDINE COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | IL5, CXCR3, TSLP | IL2 24/4885ABL1 2068/4885 |
| US-20120065239-A1 | PROCESS FOR THE PRODUCTION OF AMIDES | CFH, C5, CFB | IL2 3076/4885ABL1 1194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.